1. Home
  2. NTRA vs UTHR Comparison

NTRA vs UTHR Comparison

Compare NTRA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • UTHR
  • Stock Information
  • Founded
  • NTRA 2003
  • UTHR 1996
  • Country
  • NTRA United States
  • UTHR United States
  • Employees
  • NTRA N/A
  • UTHR N/A
  • Industry
  • NTRA Medical Specialities
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • NTRA Health Care
  • UTHR Health Care
  • Exchange
  • NTRA Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • NTRA 20.6B
  • UTHR 16.1B
  • IPO Year
  • NTRA 2015
  • UTHR 1999
  • Fundamental
  • Price
  • NTRA $160.60
  • UTHR $360.22
  • Analyst Decision
  • NTRA Strong Buy
  • UTHR Buy
  • Analyst Count
  • NTRA 15
  • UTHR 14
  • Target Price
  • NTRA $152.67
  • UTHR $370.86
  • AVG Volume (30 Days)
  • NTRA 1.0M
  • UTHR 288.8K
  • Earning Date
  • NTRA 02-26-2025
  • UTHR 02-19-2025
  • Dividend Yield
  • NTRA N/A
  • UTHR N/A
  • EPS Growth
  • NTRA N/A
  • UTHR 25.10
  • EPS
  • NTRA N/A
  • UTHR 22.72
  • Revenue
  • NTRA $1,531,955,000.00
  • UTHR $2,756,200,000.00
  • Revenue This Year
  • NTRA $53.71
  • UTHR $26.32
  • Revenue Next Year
  • NTRA $11.00
  • UTHR $10.61
  • P/E Ratio
  • NTRA N/A
  • UTHR $15.86
  • Revenue Growth
  • NTRA 54.94
  • UTHR 25.04
  • 52 Week Low
  • NTRA $58.53
  • UTHR $208.62
  • 52 Week High
  • NTRA $175.63
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 50.84
  • UTHR 46.40
  • Support Level
  • NTRA $155.12
  • UTHR $356.00
  • Resistance Level
  • NTRA $161.53
  • UTHR $365.02
  • Average True Range (ATR)
  • NTRA 5.73
  • UTHR 9.11
  • MACD
  • NTRA -1.64
  • UTHR -0.63
  • Stochastic Oscillator
  • NTRA 36.71
  • UTHR 29.69

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About UTHR United Therapeutics Corporation

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Share on Social Networks: